Epidemiology and prevention of meningococcal disease: A critical appraisal of vaccine policies

Expert Review of Vaccines

Volumn 10, Issue 12, 2011, Pages 1717-1730

  Sáfadi, Marco A P ^a,b   McIntosh, E David G ^c,d  

^a Santa Casa de Sao Paulo School of Medicine   (Brazil)

^b Hosp Sao Luiz   (Brazil)

^c Novartis Vaccines and Diagnostics   (Netherlands)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

herd protection; immunization; meningococcal disease; meningococcal vaccine; Neisseria meningitidis; public health

Indexed keywords

MENINGOCOCCUS VACCINE;

AFRICA; AUSTRALIA; BRAZIL; CANADA; CUBA; DRUG COST; EPIDEMIC; FRANCE; GREECE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; IMMUNIZATION; INCIDENCE; MENINGITIS; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NETHERLANDS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SPAIN; UNITED KINGDOM; UNITED STATES; VACCINATION;

COMMUNICABLE DISEASE CONTROL; GEOGRAPHY; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; TRAVEL;

EID: 81355149563     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.159     Document Type: Review

References (87)

1. World Health Organization. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol. Rec. 40, 331-339 (2002).
2. Van den Bruel A, Haj-Hassan T, Thompson M, Buntinx F, Mant D. European research network on recognising serious infection investigators. Lancet 375, 834-845 (2010).
3. Cummings KC, Louie J, Probert WS et al. Increased detection of meningococcal infections in California using a polymerase chain reaction assay. Clin. Infect. Dis. 46, 1124-1126 (2008). (Pubitemid 351589885)
4. Buysse CM, Vermunt LC, Raat H et al. Surviving meningococcal septic shock in childhood: long-term overall outcome and the effect on health-related quality of life. Crit. Care 14, R124 (2010).
5. Safadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurolog. Res. 32, 263-271 (2010).
6. Trotter CL, Maiden MCJ. Meningococcal vaccine and herd immunity: lessons learned from serogroup C conjugate vaccine programs. Expert Rev. Vaccines 8(7), 851-861 (2009).
7. Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50, 184-191 (2010).
8. Racloz VN, Luiz SJD. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect. Dis. 10, 175 (2010).
9. World Health Organization. Epidemics of meningococcal disease, African meningitis belt. Wkly. Epidemiol. Rec. 76, 282-288 (2001).
10. Pollard AJ, Maiden MC. Epidemic meningococcal disease in sub-Saharan Africa - towards a sustainable solution? Lancet Infect. Dis. 3, 68-70 (2003). (Pubitemid 36164199)
11. Decosas J, Koama JPT. Chronicle of an outbreak foretold: meningococcal meningitis W-135 in Burkina Faso. Lancet Infect. Dis. 2, 763-765 (2002). (Pubitemid 35434562)
12. Traoré Y, Njanpop-Lafourcade BM, Adjogble KL et al. The rise and fall of epidemic Neisseria meningitidis serogroup W-135 meningitis in Burkina Faso, 2002-2005. Clin. Infect. Dis. 43, 817-822 (2006).
13. Mutonga DM, Pimental G, Muindi J et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am. J. Trop. Med. Hyg. 80, 619-624 (2009).
14. Materu S, Cox HS, Isaakidis P, Baruani B, Ogaro T, Caugant DA. Serogroup X in meningococcal disease, Western Kenya. Emerg. Infect. Dis. 13, 944-945 (2007). (Pubitemid 46890153)
15. Delrieu I, Yaro S, Tamekloé TAS et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE 6, e19513 (2011).
16. Boisier P, Nicolas P, Djibo S et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44, 657-663 (2007).
17. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27S, B51-B63 (2009).
18. Ni JD, Jin YH, Dai B et al. Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China. Postrad. Med. J. 84, 87-92 (2008). (Pubitemid 351427574)
19. Nair D, Dawar R, Deb M et al. Outbreak of meningococcal disease in and around New Delhi, India, 2005-2006: a report from a tertiary care hospital. Epidemiol. Infect. 137, 570-576 (2009).
20. Jhamb U, Chawla V, Khanna S. Clinical profile of group A meningococcal outbreak in Delhi. Ind. Pediatr. 46, 794-796 (2009).
21. Memish ZA, Goubeaud A, Bröker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. J. Infect. Pub. Health 3, 143-151 (2010).
22. Chiappini E, Venturini E, Bonsignori F, Galli L, de Martino M. Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr. 99, 1609-1614 (2010).
23. Finn A, Clarke E, Mytton J. Adolescent immunisation: the next big thing? Arch. Dis. Child. 96(6), 497-499 (2011).
24. Ford CA, English A, Davenport AF, Stinnett AJ. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues. J. Adolesc. Health 44, 568-574 (2009).
25. Perrett KP, Winter AP, Kibwana E et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a Phase 4 clinical trial. Clin. Infect. Dis. 50, 1601-1610 (2010).
26. Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med. J. Aust. 186, 108-109 (2007). (Pubitemid 46322358)
27. Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics 23, 855-874 (2005). (Pubitemid 41317422)
28. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R. Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr. Infect. Dis. J. 28, 220-224 (2009).
29. Grimprel E. Rationale of recommendations for universal immunization against meningococcus C in France. Antibiotiques 12, 249-253 (2010).
30. Kafetzis DA, Stamboulidis KN, Tzanakaki G et al. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin. Microbiol. Infect. 13, 550-552 (2007). (Pubitemid 46563509)
31. De Greeff SC, de Melker HE, Spanjaard L et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J. 25, 79-80 (2006). (Pubitemid 43361483)
32. de Voer RM, van der Klis FRM, Niers LEM et al. Absence of Neisseria meningitides serogroup C-specific antibodies during the first year of life in The Netherlands: an age group at risk? Clin. Vaccine Immunol. 16, 1521-1523 (2009).
33. Larrauri A, Cano R, García M, de Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23, 4097-4100 (2005). (Pubitemid 40814584)
34. Centers for disease control and prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep. 60, 72-76 (2011).
35. Miller E, Salisbury DM, Ramsay ME. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20, S58-S67 2001). (Pubitemid 32925012)
36. Harrison LH, Mohan N, Kirkpatrick P. Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat. Rev. Drug Discov. 9, 429-430 (2010).
37. Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur. J. Clin. Microbiol. Infect. Dis. 29(3), 259-267 (2010).
38. Pace D. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. Curr. Opin. Mol. Ther. 11(6), 692-706 (2009).
39. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun. Dis. Pub. Health 5, 220-225 (2002).
40. Trotter CL, Andrews NJ, Kaczmarski EB et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 346, 365-367 (2004). (Pubitemid 38970013)
41. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated post licensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17, 840-847 (2010).
42. Maiden MCJ, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197, 737-743 (2008). (Pubitemid 351364476)
43. de Voer RM, Mollema L, Schepp RM et al. Immunity against Neisseria meningitides serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS One 5, e12144 (2010).
44. Deghmane AE, Parent du Chatelet I, Szatanik M et al. Emergence of new virulent Neisseria meningitidis serogroup C sequence 11 isolates in France. J. Infect. Dis. 202, 247-250 (2010).
45. Caron F, du Chatelet IP, Leroy JP et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect. Dis. 11, 455-463 (2011).
46. Safadi MAP, Barros AP. Meningococcal conjugate vaccines: efficacy and new combinations. J. Pediatr. (Rio J.). 82, S35-S44 (2006). (Pubitemid 44661479)
47. Patel M. Meningococcal disease in Australia: looking at the past, thinking of the future. Commun. Dis. Intell. 21, 233-236 (1997).
48. Simpkins D, Wood N, Jelfs J et al. Modern trends in mortality from meningococcal disease in Australia. Pediatr. Infect. Dis. J. 28, 1119-1120 (2009).
49. Australian meningococcal surveillance programme. Annual report of the Australian meningococcal surveillance programme, 2009. Commun. Dis. Intell. 34, 291-302 (2010).
50. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine. A 7-year follow-up in Quebec, Canada. Pediatr. Infect. Dis. J. 30, 566-569 (2011).
51. Nolan T, Lambert S, Marshall H et al. A novel combined Haemophilus influenza type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine 25, 8487-8499 (2007). (Pubitemid 350199589)
52. Sosa J, Llanes R, Guzman D et al. Typing and susceptibility to penicillin of Neisseria meningitidis isolated from patients in Cuba (1993-1999). Mem. Inst. Oswaldo Cruz 96, 523-525 (2001). (Pubitemid 33639644)
53. Climent Y, Urwin R, Yero D et al. The genetic structure of Neisseria meningitides populations in Cuba before and after the introduction of a serogroup BC vaccine. Infect. Genet. Evol. 10, 546-554 (2010).
54. Pérez Rodríguez A, Dickinson F, Baly A, Martin R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo Cruz 94, 433-440 (1999). (Pubitemid 129572516)
55. Laforce FM, Konde K, Viviani S, Préziosi MP. The meningitis vaccine project. Vaccine 3, A97-A100 (2007). (Pubitemid 47208599)
56. Sow SO, Okoko BJ, Diallo A et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. NEJM 364, 2293-2304 (2011).
57. Taha MK, Achtman M, Alonso JM et al. Serogroup W-135 meningococcal disease in Hajj pilgrims. Lancet 356, 2159 (2000).
58. Hoek M, Hanquet G, Heuberger S et al. European Union Invasive Bacterial Infections Surveillance Network (EUIBIS). A European survey on public health policies for managing cases of meningococcal disease and their contacts. Euro. Surveill. 13(10), pii: 8060 (2008).
59. Lennon D, Gellin B, Hood D et al. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis. J. 11, 617-623 (1992).
60. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J. Paediatr. Child Health 37, S13-S19 (2001). (Pubitemid 32989606)
61. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. 38(2), 413-418 (2009).
62. Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin. Infect. Dis. 49, 597-605 (2009).
63. Jackson C, Lennon DR, Sotutu VT et al. Phase 2 meningococcal B vesicle vaccine trial in New Zealand infants. Arch. Dis. Child. 94, 745-751 (2009).
64. Jackson C, Lennon D, Wong S et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch. Dis. Child. 96, 744-751 (2011).
65. Caugant DA, Froholm LO, Bovre K et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl Acad. Sci. USA 83, 4927-4931 (1986). (Pubitemid 16075512)
66. Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21, 734-737 (2003). (Pubitemid 36091989)
67. Borrow R, Aaberge IS, Santos GF et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12, 970-976 (2005).
68. Stefanelli P. Emerging resistance in Neisseria meningitidis and Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther. 9(2), 237-244 (2011).
69. Krause G, Blackmore C, Wiersma S, Lesneski C, Gauch L, Hopkins RS. Mass vaccination campaign following community outbreak of meningococcal disease. Emerg. Infect. Dis. 8, 1398-1403 (2002). (Pubitemid 36008775)
70. Taylor-Robinson D, Elders K, Milton B, Thurston H. Students' attitudes to the communications employed during an outbreak of meningococcal disease in a UK school: a qualitative study. J. Pub. Health 32(1), 32-37 (2010).
71. Moore PS, Reeves MW, Schwartz B, Gellin BG, Broome CV. Intercontinental spread of an epidemic of group A Neisseria meningitidis strain. Lancet 2, 260-263 (1989). (Pubitemid 19180619)
72. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W-135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin. Infect. Dis. 36, 679-683 (2003). (Pubitemid 36337970)
73. Jolley KA, Wilson DJ, Driz P, McVean G, Maiden MC. The influence of mutation, recombination, population history, and selection on patterns of genetic diversity in Neisseria meningitidis. Mol. Biol. Evol. 22, 562-569 (2005). (Pubitemid 40299505)
74. Wilder-Smith A, Barkham TM, Chew SK, Paton NI. Absence of Neisseria meningitides W-135 electrophoretic type 37 during the Hajj, 2002. Emerg. Infect. Dis. 9, 734-737 (2003). (Pubitemid 36676374)
75. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis. 14, e197-e209 (2010).
76. McIntosh EDG, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev. Vaccines 10(1), 109-129 (2011).
77. Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control of pneumococcal disease in the UK - impact of vaccination. J. Med. Microbiol. 60(Pt 1), 1-8 (2011).
78. Huang SS, Hinrichsen VL, Stevenson AR et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 124, e1-e11 (2009).
79. Parent du Châtelet I, Taha MK, Lepoutre A et al. Meningococcal invasive infections in France in 2006. Bull. Epidemiol. Hebd. 51-52, 437-441 (2007).
80. Ortega-Sanchez IR, Meltzer MI, Shepard C et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin. Infect. Dis. 46, 1-13 (2008). (Pubitemid 351263552)
81. Maiden MCJ, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197, 737-743 (2008). (Pubitemid 351364476)
82. Fernández S, Arreaza I, Santiago I et al. Impact of meningococcal vaccination with combined serogroups A and C polysaccharide vaccine on carriage of Neisseria meningitidis C. J. Med. Micro. 52, 75-77 (2003). (Pubitemid 36106372)
83. Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine 29, 1968-1973 (2011).
84. Zollinger WD, Poolman JT, Maiden MC. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev. Vaccines 10(5), 559-561 (2011).
85. Harris SL, Zhu D, Murphy E et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum. Vaccin. 7, 68-74 (2011).
86. Thulin Hedberg S, Törös B, Fredlund H et al. Genetic characterisation of the emerging invasive Neisseria meningitides serogroup Y in Sweden, 2000 to 2010. Eur. Surveill. 16(23), 19885 (2011).
87. Davila S, Wright VJ, Khor CC et al. International Meningococcal geneticsconsortium. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 42, 771-776 (2010).